Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG2 as Complementary Treatment for Fatigue in Advanced NSCLC
NCT00518869Phase 3Terminated
- Sponsor
- PhytoHealth Corporation
- Start
- Sep 2007
- Primary completion
- Jun 2008
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer-related fatigue (CRF) and neutropenia comparing PG2 + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoints: Clinical Benefit Response at 21 days and Incidence of Grade III plus IV Neutropenia at 21 days. Started Sep 2007; status: terminated.
02
Drugs
astragalus polysaccharides
03
Conditions
cancer-related fatigue (CRF)neutropenia
Beyond the preview
Go deeper on NCT00518869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00518869.